Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell potency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Cell potency. Displaying page 1 of 1.
    EudraCT Number: 2011-002863-84 Sponsor Protocol Number: Start Date*: 2012-03-02
    Sponsor Name:Medizinische Universitaet Wien, AKH Wien, Innere Medizin III, klin.Abteilung fuer Nephrologie und Dialyse
    Full Title: Calcitonin stimulation: pentagastrin vs. calcium gluconate - potency, feasibility and tolerance in chronic kidney disease.
    Medical condition: investigation of the presence/absence of C-cell abnormalities of the thyroid in chronic kidney disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000937-15 Sponsor Protocol Number: HO161 Start Date*: 2022-08-25
    Sponsor Name:UMCG
    Full Title: A phase II non-inferiority design study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma
    Medical condition: B-Cell Non Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005310-19 Sponsor Protocol Number: PI-0697-2012 Start Date*: 2013-06-05
    Sponsor Name:FUNDACION PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL_ FPA
    Full Title: Double-blind randomized clinical trial to evaluate the efficacy and safety of levosimendan as preischemic myocardial conditioner in pediatric cardiac surgery
    Medical condition: Children aged 1 month to 14 years in the health area of the province of Granada who will be undergoing heart surgery with a clinical high risk of developing acute heart failure after surgery, treat...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000271-36 Sponsor Protocol Number: KKS288 Start Date*: 2021-09-20
    Sponsor Name:Philipps University Marburg
    Full Title: Guselkumab in Patients with Oral Lichen Planus - An open label, parallel, randomized, multi- center, phase II trial
    Medical condition: severe oral lichen planus (LP) with variable phenotype (erosive, ulcerating, hyperplastic/leucoplastic, and combined forms)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10030983 Oral lichen planus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001410-41 Sponsor Protocol Number: IRST172.02 Start Date*: 2013-05-30
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastati...
    Medical condition: metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005140-33 Sponsor Protocol Number: 2015-Adf-L Start Date*: 2016-03-11
    Sponsor Name:Odense Universitets Hospital
    Full Title: Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy- randomized, placebo-controlled, double-blind clinical trial.
    Medical condition: Erectile Dysfunction Impotence of origanic origin
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004872 10021550 Impotence LLT
    18.1 100000004872 10021551 Impotence of organic origin LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001563-11 Sponsor Protocol Number: GENA-01 Start Date*: 2009-10-22
    Sponsor Name:Octapharma AG
    Full Title: Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of human-cl rhFVIII, a Newly Developed Human Cell-Line Derived Recombinant FVIII Concentrate in Previously Tr...
    Medical condition: Severe hemophilia A (FVIII:C <1%)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-005509-28 Sponsor Protocol Number: 901452-CT-21-001 Start Date*: 2022-02-10
    Sponsor Name:Akston Biosciences Corporation
    Full Title: Anti-COVID19 VaccinaTion AKS-452X BOOSTER Study (ACT-BOOSTER study)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000666-10 Sponsor Protocol Number: m16-063 Start Date*: 2018-12-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subje...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004336-16 Sponsor Protocol Number: CC-93538-EE-001 Start Date*: 2021-09-29
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject...
    Medical condition: EOSINOPHILIC ESOPHAGITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PT (Completed) BE (Completed) PL (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-020324-22 Sponsor Protocol Number: CC-10004-PSA-005 Start Date*: 2011-03-07
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) CZ (Completed) LT (Completed) IT (Completed) PL (Completed) BG (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018386-32 Sponsor Protocol Number: CC-10004-PSA-003 Start Date*: 2010-12-27
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) GB (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003902-14 Sponsor Protocol Number: EORTC-1741-GITCG Start Date*: Information not available in EudraCT
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: DKN-01/atezolizumab as second line treatment of biliarY tract cancer and in combiNAtion or not with paclitaxel as second line treatMent of esophagogastrIC cancer: a multi-center Phase II Trial
    Medical condition: Non-operable biliary tract cancer (BTC) and non-operable esophagogastric cancer (EGC) adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061203 Hepatobiliary neoplasm PT
    20.0 10019805 - Hepatobiliary disorders 10019817 Hepatobiliary neoplasms NEC HLT
    20.0 10019805 - Hepatobiliary disorders 10019811 Hepatobiliary neoplasms HLGT
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019814 Hepatobiliary neoplasms malignancy unspecified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10017947 - Gastrointestinal disorders 10017812 Gastric neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017991 Gastrointestinal neoplasms malignant and unspecified HLGT
    20.0 10017947 - Gastrointestinal disorders 10017990 Malignant and unspecified neoplasms gastrointestinal NEC HLGT
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004476-12 Sponsor Protocol Number: NCHECR001 Start Date*: 2007-07-10
    Sponsor Name:University of New South Wales
    Full Title: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection.
    Medical condition: Chronic HIV infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IE (Completed) DE (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002817-22 Sponsor Protocol Number: AAG-G-H-1624 Start Date*: 2017-02-09
    Sponsor Name:TETEC Tissue Engineering Technologies - AG
    Full Title: Prospective, Multicenter, Single-arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of NOVOCART® Inject plus in the Treatment of Cartilage Defects of the Knee
    Medical condition: Repair of cartilage defects of the knee (medial or lateral femoral condyle or tibial plateau, trochlea or patella) caused by traumatic events or osteochondritis dissecans (defect size is ≥ 4 and ≤...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000009764 10007702 Cartilage biopsy LLT
    20.0 10042613 - Surgical and medical procedures 10052913 Cartilage operation PT
    20.0 100000019132 10007705 Cartilage damage LLT
    20.0 100000022571 10057104 Cartilage repair LLT
    20.0 10042613 - Surgical and medical procedures 10064112 Cartilage graft PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) PL (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019941-24 Sponsor Protocol Number: CC-10004-PSA-004 Start Date*: 2010-12-01
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis and...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that, depending on the method of ascertainment, occurs in 6 to 39% of patients with psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) FI (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004905-26 Sponsor Protocol Number: 115649 Start Date*: 2012-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity and safety study of GSK Biologicals’ Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s MMR vaccine when both are given on a 2-dose schedule to...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10028257 Mumps PT
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    17.0 10021881 - Infections and infestations 10039252 Rubella PT
    17.0 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018385-23 Sponsor Protocol Number: CC-10004-PSA-002 Start Date*: 2010-12-17
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018646-31 Sponsor Protocol Number: CT-P13-3.1 Start Date*: 2010-10-11
    Sponsor Name:CELLTRION, Inc
    Full Title: A Randomized, Double Blind, Parallel-Group, Phase 3 Study to Demonstrate Equivalence in Efficacy and Safety of CT-P13 Compared With Remicade When Co-administered With Methotrexate in Patients With ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    12.1 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LV (Completed) GB (Completed) PT (Completed) IT (Completed) AT (Completed) LT (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:17:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA